Nexstim Wins Canadian Approval for Expanded NBS 6 Indications

02:34 AM EDT, 07/10/2026 (MT Newswires) -- Nexstim (NXTMH.HE) said Friday it secured Health Canada's approval for expanded indications of its NBS 6 system covering diagnostic applications and chronic neuropathic pain treatment. Under the expanded approval, the medical technology company can market and commercially distribute the NBS 6 for pre-procedural mapping of the speech and motor cortices of the brain, as well as for treating chronic neuropathic pain. NBS 6 was previously approved in Canada for the treatment of major depressive disorder in 2024.